Fate Therapeutics (FATE) stock

Cell therapies , market cap $222M

Cell therapies

Worth $222M

$1.77

-8.76%

As of Tuesday's close · Live for Pro members at the open

Why is FATE down?

Down 8.8% today, more than its biotech peers' 1.4%; no story names it yet.

Fell on Nov 5

Down 12% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.

It reported a diluted loss of $0.25 a share that day.

Sources: Price history, Nov 5, 2026; SEC filing, Nov 5, 2026; Company release (8-K), Nov 5, 2026

−2Long-term trend below a falling 200-day average, down over two years

Tell me next time FATE moves

Free account, no card. An optional alert when FATE moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why FATE fell on Nov 5, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Why FATE still beats the market over a year

Up 78% over the year to Nov 9 while the S&P 500 rose 12%; down 11% on Nov 5.

1 reason, from its filings, with the timeline, for Pro members.

Quality Score

-7

Poor

In its industry

#240of 281

Biotech

Checks firing

1of 14

Choppy

From 52-week high

-45.2%

under its best in a year

FATE's Quality Score fell 5 points on Tue, Nov 10, to -7. Sales fell 33% on the year, from a 33% drop.

Follow FATE's trial news. Pro members can get an alert when Fate Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when FATE files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next1H 2028“…availability of FT819, the Company aims to complete enrollment of RECLAIM-LN in the first half of 2028…”Trial start · SEC filing · Aug 13

Cash$139M, about 5 quarters at the last year's spendingOn Sep 30 · raised money since, not counted · the company says “into 2028”

Key facts on FATE

Key facts on FATE
Since its Dec 2021 high	Down 97% sales $55.8M → $4.8M a year
Latest filing	8-K, Nov 5 Signed a material agreement and ended a material agreement

1 more reason behind FATE's -7, free with an account →3 more reasons behind FATE's -7, for Pro members.

FATE in the news

TodayNo story names it yet.

What's next

Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$139M, about 5 quarters at the last year's spendingOn Sep 30 · raised money since, not counted · the company says “into 2028”

FATE catalysts

Coming up

After its last 4 reports it closed -4.6% on average, higher 1 of 4 times.

9 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for FATE, and how long its cash lasts

Next step the company has named

1H 2028“…in the Phase 1 clinical trial, current clinical site engagement, and the on-demand availability of FT819, the Company aims to complete enrollment of RECLAIM-LN in the first half of 2028.”Trial start · SEC filing · Aug 13

What it means: when a trial begins, or reaches the stage the company named.

Lead program: FT819 · Lupus Nephritis · Phase 2
Its trial: RECLAIM-LNPhase 2 · Recruiting · 53 people · main data estimated Jul 1, 2029 · NCT07570862

5 more trials, 29 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 5 quarters

$139M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2028” (8-K, Aug 13). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO Kamal Adawi sold 6,582 shares on Nov 3. 6 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Bahram Valamehr buys or sells

For Pro members: every trade, and Bahram Valamehr’s 15 filings and quotes.

Get an alert when FATE files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How FATE ranks in Biotech

FATE is #240 of 281 by Quality Score.

How FATE ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	EWTXEdgewise Therapeutics		Open for its score
	EXELExelixis		Open for its score
	FDMT4D Molecular Therapeutics		Open for its score
	FHTXFoghorn Therapeutics		Open for its score
240	FATEFate Therapeutics	1/14	-7

When does FATE report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What FATE reported on Nov 5, 2026

The quarter

A loss of $0.25 a share, from $0.27.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

FATE's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value: $222M; today
Sales: $4.8M; down 33.5% on the year
Free cash flow: -$107M; last 12 months

Sales fell 59% a year over 3 years, fiscal 2022 to 2025.

Its share count grew 7.6% a year over 5 years.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on FATE: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+5.4%-5.1%-7.3%-11.5%

Feb 26May 13Aug 13Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	-5.7%	-11.5%	not yet
Aug 13, 2026Before open	Before open	+4.0%	-7.3%	-2.6%
May 13, 2026Before open	Before open	-2.7%	-5.1%	-16.0%
Feb 26, 2026Before open	Before open	-1.4%	+5.4%	-2.0%

FATE closed higher after 1 of its last 4 reports.

FATE sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $6.6M in 2025. It lost money in each of the eight years.

FATE has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on FATE, and all 14 on every stock.Get in free →

FATE RSI today: 35.6, below its 50-day and 200-day averages

Not scored

RSI 35.6, MACD below signal, below both averages. Not scored.13 readings

The deep dive on FATE

What it does and how it makes money6 findingsAn operating loss of $148M in fiscal 2025, on $6.65M of sales.Annual report, filed Feb 26, 2026"In addition … we are eligible to receive tiered royalties (Royalties) ranging from the mid-single digits to the low-double digits based on annual net sales by Ono for each Candidate in such territories, with the Royalties subject to certain reductions." (10-K for fiscal 2025)SEC filing · Feb 26, 2026"We expect U.S. patents related to this technology to have statutory expiration dates starting in 2039." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
What changed in its filings8 findings"On September 24, 2026, the court denied our motion to dismiss and permitted claims concerning four alleged misstatements made in 2022 to proceed." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026A new heading in its "Risk Factors" this year: "Our clinical trials may be adversely affected by investigators’ limited experience with CAR-T cell therapies, including lack of familiarity with CAR-T-specific safety profiles and adverse events, which could impact patient safety, safety reporting …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 26, 2026, against the one of Mar 5, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades FATE, for Pro members

11 more findings on FATE, each with its source, for Pro members.

FATE share count over time

4% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of FATE outstanding, as filed
Shares outstanding	As of
121.6M	Oct 30, 2026
119.8M	Aug 6, 2026
116.6M	May 7, 2026
116.3M	Feb 19, 2026

Offerings, shelves, and splits of FATE, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 45% of its market value	Nov 5, 2026
Registered shares for a later sale (S-3)	Nov 5, 2026
Registered shares for a later sale (S-3)	Apr 18, 2024
Raised $14,545 in a sale of shares	Mar 20, 2024

FATE insider trades

3 insiders sold $320K across 5 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellKamal Adawi$14KChief Financial Officerat $2.05 on Nov 3, filed Nov 4

SellKamal AdawiChief Financial Officer$14Kat $2.05 on Nov 3, filed Nov 4

All 5 insider filings on FATE from the last six months, for Pro members.

FATE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Bahram ValamehrPresident and CEO · 3 trades
Kamal AdawiChief Financial Officer · 1 trade
Cindy TahlOfficer · 3 trades
Robert S. EpsteinDirector · no trades on file
William H. RastetterDirector · no trades on file

See insider trades by person

Which ETFs hold FATE?

In ETFs: FATE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

161 employeesSan Diego, CAfatetherapeutics.com

What Fate Therapeutics says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapid innovation, intense and dynamic competition and a strong emphasis on proprietary products.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on FATE and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn FATE's score around: 8 things
8 more filings explained, a plain line each
4 more things pulling FATE's score down

BreakawayNov 4Kamal Adawi sold FATE$14K at $2.05, filed Nov 4

Alerts are optional.

See FATE's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: FATE's Quality Score is -7 (Poor), #240 of 281 in Biotech. Insiders sold $320K in the last 6 months (Form 4).

What does FATE's Quality Score say?

FATE scores -7 today, which Breakaway calls Poor. It is #240 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 12% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Cash lasts about 5 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is FATE's Quality Score?

FATE scores -7 today, which Breakaway calls Poor (below zero). That is #240 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FATE's -7.

Are insiders buying FATE?

3 insiders sold $320K across 5 filings in the last 6 months. No open-⁠market buys on record. The newest is Kamal Adawi, Chief Financial Officer, who sold $14K on Nov 3. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.